Heilongjiang Sunflower Pharmaceutical Group Co., Ltd., a famous brand in Heilongjiang, is famous for its gastrointestinal drugs represented by Gastric Kangling and children's drugs represented by Pediatric Pulmonary Fever, Cough and Asthma Oral Liquid

Sunflower Pharmaceutical Group is a large-scale private pharmaceutical enterprise group focusing on Chinese patent medicines, supplemented by chemical drugs, biological drugs and tonic health care products, integrating drug manufacturing, marketing and scientific research. Now it has 12 pharmaceutical production enterprises, 4 pharmaceutical companies, 1 pharmaceutical research institute, 1 medicinal material planting base, 1 pharmaceutical packaging material company, including Wuchang sunflower, Yichun sunflower, Jiamusi sunflower, Jiamusi (Luling) sunflower, Tangshan sunflower, Hengshui sunflower, Jizhou sunflower, Chongqing sunflower, Longzhong sunflower, Wudang sunflower, Linjiang sunflower, Guizhou sunflower, etc. The Group is one of the "Top 100 Pharmaceutical Enterprises in China", "Top 50 Pharmaceutical Growth Companies in China" and "Top 20 Listed Pharmaceutical Companies in China". In 2014, it was successfully listed on the Shenzhen Stock Exchange (stock code: 002737).

Under the leadership of Mr. Guan Yanbin, Chairman of the Board of Directors and President, the Group created the "Sunflower Phenomenon" that maintained a 300% development rate for four consecutive years in the early stage of restructuring, and has maintained stable, healthy and sustainable development since then. Mr. Guan Yanbin is a national model worker, a national outstanding builder of socialism with Chinese characteristics, an outstanding private entrepreneur in China, one of the top ten leaders in China's pharmaceutical industry in 2014, a person of the year in China's pharmaceutical economy in 2015, a deputy to the 11th and 12th National People's Congress, and an executive vice president of the Pharmaceutical Chamber of Commerce of the All-China Federation of Industry and Commerce.

In terms of product layout, from a product in the early stage of the restructuring to the world, it has now developed into 15 dosage forms and 1132 drug approval numbers, of which there are 29 exclusive varieties, 566 varieties of medical insurance catalogue and 274 varieties of essential drugs, forming 6 characteristic product clusters of pediatrics, gynecology, digestive system, respiratory cold, rheumatism and bone injury and cardiovascular and cerebrovascular chronic diseases, and completing the transformation from varieties to brands and categories.

In terms of scientific and technological research and development, Sunflower has successfully developed well-known traditional Chinese medicine products represented by liver protection tablets and stomach health capsules, and has made outstanding contributions to the development of China's traditional Chinese medicine industry. At present, Beijing and Harbin have set up pharmaceutical research institutes, and scientific research institutes have been set up in each enterprise, focusing on the research and development of high-tech new preparations for traditional Chinese medicine, natural medicine, and chemical drugs, and continuously improving the innovation and development ability of enterprises through the R&D strategy of "buying, reforming, linking and researching".

In terms of competitive advantage, the group has formed a unique "five competitive advantages". First, the advantage of independent brands. Relying on China's well-known "Sunflower" trademark, the national leading brand "Little Sunflower Children's Medicine" and 4 provincial famous trademarks, we strive to build the main brand of "Sunflower", the leading brand of "Little Sunflower" children's medicine, the characteristic brand of "Meixiaohu" gynecological medicine, the ultra-high-end top secret brand of "private medicine", and the sub-brand of big health. The second is the advantage of its own varieties. Sunflower has 6 major product lines: children's medicine, gynecological medicine, respiratory and cold medicine, digestive system medicine, rheumatism and bone injury medicine and cardiovascular and cerebrovascular chronic disease medicine, which are gathered into a rich product line. The third is the advantage of self-built networks. Sunflower has 4 marketing companies, 16 business divisions, more than 300 marketing teams, and has established partnerships with more than 800 pharmaceutical commercial customers, 2,350 large and medium-sized pharmaceutical chain pharmacies, and 3,000 hospitals, forming a huge industry-leading marketing network. Fourth, the advantages of automatic control terminals. Relying on its own brand advantages and network advantages, Sunflower has firmly grasped the initiative of terminal sales, and its products cover more than 300,000 drug terminals at all levels. Fifth, self-promotion advantages. The complete market-oriented operation of marketing activities makes the products more competitive in the field of circulation and in front of consumers.

In terms of social responsibility, Sunflower has always been keen on public welfare, actively fulfilling social obligations and assuming social responsibility. First, it undertook large-scale public welfare activities such as the "First National Conference on the Dissemination and Development of Children's Safe Drug Use", and created public welfare platforms such as "Little Sunflower Mother Classroom" and "Pediatric Medicine Online", taking the dissemination of the concept of children's safe drug use and caring for the healthy growth of children as its responsibility and mission; Second, Sunflower has invested nearly 50 million yuan to donate to social charity, carry out disaster relief and poverty alleviation, send free medicine to the countryside, advocate safe drug use and other public welfare activities; Third, in the process of enterprise development, a large number of labor force employment has been solved, most of which are college graduates and laid-off workers.

In accordance with the group's strategic development plan, Sunflower people are fully implementing the development strategy of "variety is king, characteristic management, model leading, and competition in the whole industry chain", and is moving forward towards the goal of "double hundred sunflowers" and "thousands of sunflowers", that is, to build a sunflower aircraft carrier with a sales scale of more than 10 billion yuan, more than 100 billion yuan, and a century-old reputation of world-class brands, so as to make greater contributions to the development of society and human health!